The global landscape of ocular health is on the verge of a significant transformation, poised for a remarkable surge with the Global Ocular Tuberculosis Therapeutics Industry projected to reach a noteworthy US$753.2 million valuation by 2032. This forecast showcases a substantial increase from the US$405.0 million recorded in 2022, highlighting the industry’s impressive growth trajectory.
The driving force behind this extraordinary growth is the robust Compound Annual Growth Rate (CAGR) of 5.8%, as unveiled in a comprehensive forecast by industry analysts. This forecast not only underscores the industry’s resilience but also indicates a compelling demand for ocular tuberculosis therapeutics. This surge marks a pivotal shift in the global ocular health landscape.
Global Ocular Tuberculosis Therapeutics Industry: Overview: There are different mechanisms through which ocular tuberculosis may occur, involving the lid, conjunctiva, cornea, and sclera. In past years there has been a rise in the prevalence of tuberculosis owing to which there is an increasing government involvement and awareness programs.
The increased awareness of Ocular Tuberculosis Therapeutics and the active participation of government organizations is anticipated to drive the growth of the Ocular Tuberculosis Therapeutics market over the forecast. In April 2017, Cebu City Jail made HIV and tuberculosis testing mandatory for the inmates. To date, there are 135 inmates diagnosed with HIV and 32 with tuberculosis. Seventeen inmates have died due to various illnesses. Apart from some of the inmates already having tuberculosis or HIV, there is no proper medical check-up protocol when an inmate is transferred to the facility, and jail cells are congested.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-5056
This lack of medical check-up protocol is expected to hinder the growth of the Global Ocular Tuberculosis Therapeutics Industry over the forecast period. Based on treatment type, the Global Ocular Tuberculosis Therapeutics Industry is segmented into First line treatment & Second line treatment. The second line of treatment for Ocular Tuberculosis Therapeutics includes Fluoroquinolones, Aminoglycosides, Cycloserine, Polypeptides, p-aminosalicylic Acid & Thioamides. Combination treatment for Ocular Tuberculosis is anticipated to witness significant growth in the overall Ocular Tuberculosis Therapeutics market.
Global Ocular Tuberculosis Therapeutics Industry: Drivers and Restraints
The primary driver of ocular tuberculosis therapeutics is the increasing number of cases in the population. For instance, according to the WHO 2015 report, there were 9,557 tuberculosis cases (a rate of 3.0 cases per 100,000 persons) in the United States, a 1.6% increase in the number of TB cases compared to cases reported in 2014. Moreover, regulatory reforms to support a regime or combination of drug treatment rather than a single medicine are also expected to boost the demand for the Global Ocular Tuberculosis Therapeutics Industry
In August 2016, the European Medicines Agency (EMA) launched a public consultation on revised guidance for companies developing new drugs to treat tuberculosis. EMA feels that the current treatment and the guidelines cannot address the problem as they are slow, complex, and lengthy and develop multiple drug-resistant tuberculosis. Tuberculosis is caused by a causative agent named Mycobacterium tuberculosis, which can lead to affecting any part of the body including the eye. When ocular tuberculosis is struck by mycobacterium tuberculosis it can affect any part of the eye including the superficial, intraocular, or area surrounding the eye.
With or without systemic involvement. Secondary ocular tuberculosis occurs due to the hematogenous spread from distant sites or sometimes by direct invasion from adjacent structures, like the sinus or cranial cavity. Posterior uveitis is the most common presentation of intraocular TB while it forms an initial presentation of extra-pulmonary dissemination of infection.
Ocular Tuberculosis Therapeutics Industry: Region-wise Outlook
In terms of geography, the ocular tuberculosis therapeutics market has been divided into seven regions including North- America, Eastern Europe, Western Europe, and Asia- Pacific excluding Japan, Japan Middle & Africa, and Latin America. North America Ocular Tuberculosis Therapeutics is expected to remain the dominating region while Asia Pacific Ocular Tuberculosis
Therapeutics is expected to emerge as the fastest-growing region. In the Asia Pacific region apart from the huge population base and the high prevalence rate of tuberculosis, there are research grants offered by the various organizations in Ocular Tuberculosis Therapeutics to bring in more product developments. Such investment is encouraging academic and corporate partnerships to focus on Ocular Tuberculosis Therapeutics development and commercialization. In June 2017, Dr Soumyava Basu received a grant of US$ 46,638 from the Department of Health Research (DHR) and the Indian Council of Medical Research (ICMR) to conduct a clinical trial on ocular TB research.
Ask from Market Research Expert
https://www.futuremarketinsights.com/ask-question/rep-gb-5056
Global Ocular Tuberculosis Therapeutics Industry: Key Market Participants
Some of the Global Ocular Tuberculosis Therapeutics Industry participants are AstraZeneca, Bayer HealthCare AG, Biological E, BioVersys, Cadila Pharmaceuticals, Concept Pharmaceuticals Ltd., Infectex, Johnson & Johnson, Labatec-Pharma SA, Lupin Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Maneesh Pharmaceuticals, Novartis, Otsuka Novel Products, Pfizer, Pharmasyntez, Sandoz, Sanofi, Sequella, Inc., and Themis Medicare Ltd.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
The report covers an exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
The regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, UK, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia-Pacific (China, India, ASEAN, Australia & New Zealand)
- Japan
- The Middle East and Africa (GCC, S. Africa, N. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Click Here To Buy Your Detailed Report
https://www.futuremarketinsights.com/checkout/5056
Global Ocular Tuberculosis Therapeutics Industry: Segmentation
Based on treatment, the Global Ocular Tuberculosis Therapeutics Industry can be segmented as:
- First line treatment
- Rifampicin
- Isoniazid
- Ethambutol
- Pyrazinamide
- Second line treatment
- Fluoroquinolones
- Aminoglycosides
- Cycloserine
- Polypeptides
- p-Aminosalicylic Acid
- Thioamides
- Combination Therapy
Based on end user, the Global Ocular Tuberculosis Therapeutics Industry can be segmented as:
- Hospital
- Clinics
- Ambulatory Surgical Centers
Report Highlights:
- Detailed overview of the parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube